The QualityStocks Daily Friday, April 12th, 2024

Today's Top 3 Investment Newsletters

SeriousTraders(PXMD) $0.8390 +103.71%

QualityStocks(HUSA) $2.1600 +35.00%

Tiny Gems(NXPL) $1.8700 +24.67%

The QualityStocks Daily Stock List

Houston American Energy (HUSA)

Wall Street Resources, UndiscoveredEquities, Jason Bond, StockMarketWatch, MarketClub Analysis, MarketBeat, QualityStocks, StocksEarning, Prism MarketView, The Street, TheStockfather, Stock Analyzer, TradersPro, MonsterStocksPicks, Stock Stars, INO Market Report, BUYINS.NET, Dynamic Wealth Report, StreetInsider, InvestorPlace, Greenbackers, Daily Trade Alert, Mega Stock Pick, Mega Stock Picks, OTCPicks, PennyPro, PoliticsAndMyPortfolio, Promotion Stock Secrets, The Online Investor, TopPennyStockMovers, Trades Of The Day, Trading Markets, UltimatePennyStock and PowerRatings Stocks reported earlier on Houston American Energy (HUSA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Houston American Energy Corp. (NYSE American: HUSA) is an independent energy firm focused on the acquisition, exploration, development and production of condensate, crude oil and natural gas properties.

The firm has its headquarters in Houston, Texas and was incorporated in 2001, on April 2nd. It serves consumers in South America and the United States Gulf Coast region.

The company’s gas and oil operations and assets are mainly found in the onshore Gulf Coast region, especially in Louisiana, Texas and Colombia. It manages its resources via divestitures and acquisitions. Its development and exploration projects are focused on future acquisition of more property interests in South America and in particular, Colombia, as well as the Texas Permian Basin, Louisiana and the onshore Texas Gulf Coast region. It is also focused on its existing property interests. The company also holds some acreage in Oklahoma.

The enterprise’s exploration and producing properties in Texas comprise of the Matagorda County while its properties in Louisiana include the Jefferson Davis Parish, the Assumption Parish, the Iberville Parish, the Vermilion Parish, the Plaquemines Parish and the East Baton Rouge Parish. As of December 2020, the enterprise owned interests in 4 gross wells, with reported proved reserves of over 115,000 barrels of oil equivalent.

As of November 2020, the firm had appointed a new CEO who brings with him years of industry experience and an understanding of the firm’s operations and assets, which will help bring in more opportunities to the company, which will be good for its growth.

Houston American Energy (HUSA), closed Friday's trading session at $2.16, up 35%, on 15,134,075 volume. The average volume for the last 3 months is 386,559 and the stock's 52-week low/high is $1.27/$2.87.

Virios Therapeutics (VIRI)

RedChip, QualityStocks, MarketClub Analysis, TradersPro, Red Chip, PennyStockScholar, PCG Advisory, MarketBeat and 247 Market News reported earlier on Virios Therapeutics (VIRI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Virios Therapeutics Inc. (NASDAQ: VIRI) is a development stage biotechnology firm that is engaged in the development and commercialization of antiviral treatments for ailments linked to viral triggered abnormal immune responses.

The firm has its headquarters in Alpharetta, Georgia and was incorporated in 2012, on February 28th by William L. Pridgen. Prior to its name change in December 2020, the firm was known as Virious Therapeutics LLC. It operates in the health care sector, under the biotech and pharma sub-industry and serves consumers in the U.S.

The company’s objective is to enhance patient outcomes by finding the underlying cause of fibromyalgia as well as other conditions. Scientists propose that the overactive immune responses associated with activation of HSV-1 (Herpes Simplex Virus-1) tissue may be a possible cause of chronic ailments like functional somatic syndrome, chronic fatigue syndrome, irritable bowel disease and fibromyalgia. All these diseases are characterized by a waning and waxing manifestation of illness.

The enterprise’s lead drug candidate is a fixed dose combination of celecoxib and famciclovir known as IMC-1, which has been indicated for the treatment of fibromyalgia. Its end goal is to decrease viral-mediated illness burdens. The candidate is currently undergoing a phase 2b clinical trial, which is expected to end by the first quarter of 2022.

The firm’s IMC-1 candidate was recently awarded fast track designation by the FDA. The candidate, which has shown promising results, may soon be introduced to the market, which will not only benefit the patients who suffer from fibromyalgia but also bring in more investors into the firm.

Virios Therapeutics (VIRI), closed Friday's trading session at $0.512399, up 6.7723%, on 372,229 volume. The average volume for the last 3 months is 356,512 and the stock's 52-week low/high is $0.279/$2.42.

Theravance Biopharma (TBPH)

MarketBeat, MarketClub Analysis, InvestorPlace, Investopedia, Kiplinger Today, The Online Investor, Zacks, Trades Of The Day, Daily Trade Alert,, StockMarketWatch, QualityStocks, StreetInsider, BUYINS.NET, Wyatt Investment Research, Investiv, Investing Daily and Darwin Investing Network reported earlier on Theravance Biopharma (TBPH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Theravance Biopharma Inc. (NASDAQ: TBPH) (FRA: 0TB) is a biopharmaceutical firm that is focused on discovering, developing and commercializing organ-selective medications.

The firm has its headquarters in George Town, the Cayman Islands and was incorporated in July 2013. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector. The firm has four companies in its corporate family and serves consumers in the U.S. as well as in Asia and Europe.

The company is party to licensing and collaboration agreements with Takeda Pharmaceutical Company Ltd, Alfasigma S.p.A, Janssen Biotech Inc. and Pfizer Inc.

The enterprise’s pipeline comprises of a nebulized muscarinic antagonist dubbed Yupelri, which has been developed to treat chronic obstructive pulmonary disease. It also provides a selective 5-HT4 agonist indicated for the treatment of gastrointestinal motility disorders; a pan-janus kinase inhibitor dubbed Izencitinib, which is currently in a phase 2b/3 clinical trial evaluating its effectiveness in treating ulcerative colitis, myelofibrosis and rheumatoid arthritis, as well as various inflammatory intestinal diseases which include Crohn’s disease and ulcerative colitis. In addition to this, it also provides Trelegy, also indicated for the treatment of chronic obstructive pulmonary disease; a gut-selective JAK3inhibitor known as TD-5202, which is in a phase 1 clinical study testing its effectiveness in treating inflammatory intestinal diseases; and an investigational reuptake inhibitor known as Ampreloxetine, which has concluded its phase 3 study and is indicated for the treatment for neurogenic orthostatic hypotension.

The company is focused on leveraging its expertise in developing respiratory therapeutics in an effort to maximize shareholder value. This move is bound to bring in more investors into the company and boost its growth.

Theravance Biopharma (TBPH), closed Friday's trading session at $9.61, up 7.6148%, on 783,427 volume. The average volume for the last 3 months is 167,050 and the stock's 52-week low/high is $8.21/$12.03.

Sensus Healthcare (SRTS)

MarketBeat, TradersPro, TraderPower, Zacks, StockMarketWatch, QualityStocks, InvestorPlace, Daily Trade Alert, Trades Of The Day, The Online Investor, StreetInsider, MarketClub Analysis and INO Market Report reported earlier on Sensus Healthcare (SRTS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sensus Healthcare Inc. (NASDAQ: SRTS) (FRA: 5TX) is a medical device firm that develops cost-effective, minimally invasive as well as non-invasive treatments for both non-oncological and oncological skin conditions, which have been proven to be highly effective.

Sensus Healthcare Inc. was founded by Stephen Cohen, Richard Golin, Kalman Gishman and Joseph C. Sardano in May 2010 and is based in Boca Raton, Florida. The company is a part of the Medical Equipment and Supplies Manufacturing Industry and serves consumers from all over the world. Sensus Healthcare Inc.’s revenue is generated primarily in the United States.

The company uses a low-energy X-ray technology termed as SRT (superficial radiation therapy), which it incorporated into its treatment device portfolio. The devices include the SRT-100 Vision, the SRT-100+ and the SRT-100. Its superficial radiotherapy system is used by dermatologists and oncologists to offer patients who opt out of surgery an alternative way to treat squamous cell and basal cell skin cancer, as well as other skin conditions, like keloids. Sensus Healthcare Inc. also provides a professional skin care line, known as Sensus Skin Solutions.

Sensus Healthcare Inc. recently introduced its ScultpturaTM robotic radiation oncology system which offers brachytherapy and triple-modulated intraoperative radiotherapy to treat patients who are going through treatment for cancer in surgery or at the site of the tumor in an efficient and fast way.

The firm recently received a patent for its Sculptura system, which will allow for more ways to deliver radiation to treat all types of solid tumors. Sensus Healthcare Inc. enhances the quality of life of patients across the globe and with its latest design, may make it easier to treat cancerous tumors, which makes the potential demand of the product pretty high.

Sensus Healthcare (SRTS), closed Friday's trading session at $3.38, up 7.6433%, on 140,274 volume. The average volume for the last 3 months is 14.43M and the stock's 52-week low/high is $1.79/$5.38.

XPeng Inc. (XPEV)

InvestorPlace, MarketClub Analysis, Schaeffer's, StocksEarning, StockEarnings, MarketBeat, Kiplinger Today, The Street, Early Bird, INO Market Report, The Online Investor, Zacks, Trades Of The Day, Daily Trade Alert, StreetInsider, Cabot Wealth, FreeRealTime, CNBC Breaking News, BUYINS.NET, Earnings360, Louis Navellier, wyatt research newsletter, The Stock Dork, 360wallstreet, TipRanks, The Wealth Report and Investopedia reported earlier on XPeng Inc. (XPEV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

XPeng Inc. (NYSE: XPEV) (HKG: 9868) (BMV: XPENV) is a smart electric vehicle firm focused on designing, developing, manufacturing and marketing smart electric vehicles.

The firm has its headquarters in Guangzhou, China and was incorporated in 2015 byXiao Peng He, Heng Xia, and Tao He. It operates as part of the auto manufacturers industry, under the consumer cyclical sector. The firm serves consumers in the People’s Republic of China.

The company aims to develop full-stack autonomous driving technology, in-car intelligent operating systems and core vehicle systems in-house through the its proprietary software, core hardware and data technologies. It is party to a strategic partnership with DiDi Global Inc., focused on enhancing the adoption of smart electric vehicles and technologies.

The enterprise develops driver-assistance system technology and an in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. Its offerings include SUVs under the G3, G3i, and G9 names; family sedans under the P5 name; and 4-door sports sedans under the P7 and P7i names. It also offers a range of services to its clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The enterprise’s smart electric vehicles primarily target the mid- to high-end segment in China’s passenger vehicle market. It sells its vehicle products under the brand Xpeng.

The firm recently expanded its footprint via a partnership with Hong Kong’s Sime Darby Motors, a move that will allow Xpeng to bring its latest smart electric vehicles to local consumers in the Hong Kong market. This may, in turn, bring in additional revenues into the firm while also opening it up to new growth and investment opportunities.

XPeng Inc. (XPEV), closed Friday's trading session at $7.46, off by 9.7944%, on 16,771,366 volume. The average volume for the last 3 months is 70.182M and the stock's 52-week low/high is $7.18/$23.62.

Palantir technologies Inc. (PLTR)

Kiplinger Today, InvestorPlace, Schaeffer's, MarketClub Analysis, INO Market Report, MarketBeat, StockEarnings, The Street, Early Bird, StocksEarning, Zacks, Trades Of The Day, Daily Trade Alert, The Online Investor, Top Pros' Top Picks, InvestorsUnderground, StreetInsider, Cabot Wealth, The Night Owl, The Wealth Report, Investopedia, CNBC Breaking News, FreeRealTime, Investment House, Earnings360, Smartmoneytrading, TradersPro, Smart Investing Society, DividendStocks, Prism MarketView, bullseyeoptiontrading, AllPennyStocks, InsiderTrades, Lance Ippolito, 360wallstreet, OTC Stock Review, QualityStocks, Rick Saddler, The Stock Dork, Tim Bohen, Wealth Insider Alert, wyatt research newsletter and Money Morning reported earlier on Palantir technologies Inc. (PLTR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recently conducted survey has determined that artificial intelligence use will decrease the number of workers at thousands of companies over the next five years. Two thousand executives took part in the survey, which was carried out by Adecco Group, a Swiss staffing company, in collaboration with Oxford Economics.

The survey also found that 41% of executives expected to employ fewer individuals because of the advancements in technology. The poll’s results show the potential for artificial intelligence, which can create original images, text and other content in response to prompts, to revolutionize how individuals work and employment in general.

In a statement, Adecco Group CEO Denis Machuel stated that artificial intelligence was emerging as a great disruptor in work, noting that companies needed to do more to reskill and redeploy teams to capitalize on this technological leap.

The polled executives work in 18 industries, including retail, energy and the automotive sector, in nine countries. These countries include Canada, United States, Japan and Germany. Their workforces represent blue-collar and white-collar jobs.

About 46% of respondents revealed that they would redeploy employees internally if their work was affected by artificial intelligence. Additionally, two-thirds of respondents revealed that they planned to recruit individuals skilled in artificial intelligence compared to one-third who preferred to train their existing workforce in AI.

This isn’t the first poll to look at AI’s effects on employment.

A separate survey carried out by the World Economic Forum in 2023 found that in more than 80 international companies, about one-quarter expected artificial intelligence to cause some people to lose their jobs. Half of the companies surveyed also expected artificial intelligence to create new employment opportunities.

In their report, the World Economic Forum stated that employers expected most technologies, artificial intelligence included, to be a net positive for jobs in the next five years. The agency noted that climate change, big data analytics and environmental management technologies as well as cybersecurity and encryption were expected to be the largest drivers of job growth.

While this outlook is positive, it provides little consolation to employees who have already lost their work to artificial intelligence. In the last year, tech companies such as Duolingo and Dropbox revealed artificial intelligence was the primary reason for recent layoffs.

Economists at Goldman Sachs stated in 2023 that about 300 million jobs could diminish or be lost worldwide by the rise of generative artificial intelligence. White-collar workers expect to be hit the hardest.

For AI companies such as Palantir technologies Inc. (NYSE: PLTR), the software solutions developed are geared at helping companies analyze data and make better business decisions. Some job losses could occur in the long run, but reducing employee numbers is often not an objective.

Palantir technologies Inc. (PLTR), closed Friday's trading session at $22.67, off by 0.744308%, on 36,764,458 volume. The average volume for the last 3 months is 6.703M and the stock's 52-week low/high is $7.28/$27.50.

QuantumScape Corp. (QS)

InvestorPlace, StockEarnings, Schaeffer's, StocksEarning, QualityStocks, MarketClub Analysis, The Street, MarketBeat, GreenCarStocks, The Online Investor, Cabot Wealth, Daily Trade Alert, Top Pros' Top Picks, FreeRealTime, BUYINS.NET, CNBC Breaking News, Green Energy Stocks, wyatt research newsletter, Atomic Trades, Trades Of The Day, Zacks, TipRanks and INO Market Report reported earlier on QuantumScape Corp. (QS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent study by the RAC Foundation has revealed that patchy phone signals could potentially hinder battery electric vehicle (BEV) adoption in the United Kingdom. According to the study, poor phone signals in the country could make it difficult for electric vehicle drivers to use up to one-third of the most common public EV chargers in the UK.

The RAC Foundation noted that this poor connectivity could potentially “undermine” the public’s confidence in EV charging infrastructure. Unfortunately, the public is already wary of public EV chargers because they are too insufficient to support the nation’s growing number of electric cars and tend to experience reliability issues.

For EV drivers who can’t afford to install private home chargers or don’t have a garage or driveway to host the charger, public-charging infrastructure is one of the only ways they can keep their EVs charged. Most of the EV charging stations in the UK typically require drivers to download and use applications to operate the chargers.

However, the RAC Foundation’s research found that 66% of Type-2 chargers in the UK (excluding London) are located in places where at least one mobile network provider doesn’t offer usable 4G network coverage. This is despite the fact that most level-2 public electric-vehicle chargers in the country cannot function without a high-quality mobile connection and have to be accessed via mobile apps.

The foundation’s report warned that drivers will continue to face the risk of being unable to charge their electric cars if all four mobile network providers in the UK — O2, EE, Vodafone and Three — don’t provide enough network coverage where public EV charging infrastructure is located. Since EV charging typically takes longer and involves more hassle compared to fueling internal combustion engine (ICE) cars, this issue could potentially dissuade more drivers from switching to EVs.

RAC Foundation director Steve Gooding notes that the millions of petrol and diesel-powered vehicle drivers in the UK can easily and quickly fill up their cars at any of the more than 8,000 stations in the country. Unfortunately, BEV drivers don’t enjoy the same convenience, Gooding said.

In this case, poor connectivity might lead EV drivers to the false assumption that the EV charger itself is faulty, reducing the public’s already low confidence in public electric-vehicle charging infrastructure. This could, in turn, exacerbate range anxiety, an issue that has prevented many drivers from ditching their internal combustion engine cars in favor of battery electric vehicles. Gooding adds that the UK government’s novel mandatory reporting system won’t pick up on the poor connectivity issues plaguing the country’s network of type-2 chargers because it will only deal with the rapid-charging network.

Authorities in the UK need to take steps to address concerns about phone signal reliability so that motorists have greater interest in not just UK-made EV models but also those from overseas, such as electric vehicles made by QuantumScape Corp. (NYSE: QS).

QuantumScape Corp. (QS), closed Friday's trading session at $5.81, off by 3.9669%, on 5,362,645 volume. The average volume for the last 3 months is 999,125 and the stock's 52-week low/high is $4.99/$13.86.

Cresco Labs Inc. (CRLBF)

InvestorPlace, QualityStocks, Kiplinger Today, Daily Trade Alert, MarketBeat, Cabot Wealth, Top Pros' Top Picks, The Street, The Wealth Report, The Online Investor, Wealth Insider Alert, Trading For Keeps, Trades Of The Day, Early Bird, Prism MarketView, StreetInsider, wyatt research newsletter, TradersPro and StocksEarning reported earlier on Cresco Labs Inc. (CRLBF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Last week, an Albany judge overturned New York’s rules on marijuana advertising and marketing. In his ruling, Judge Kevin Bryant stated that the rules were a violation of free speech and commerce. This ruling throws the state’s already struggling legal marijuana industry into confusion.

In 2023, the state was prevented from issuing licenses to new marijuana shops for months, which left many shops unopened and allowed unlicensed retailers to operate across the city. In his 13-page ruling, Judge Bryant explained that the Office of Cannabis Management (OCM) published regulations outlawing marketing and promotions on third-party platforms with no evidence to support its edicts.

The judge added that there was nothing in the record to determine precisely how the OCM came up with its regulations. The judge’s ruling also cast aside the ban that covered price listings for marijuana products such as joints, loose flower and gummies. In addition to this, the judge ordered the state of New York to pay for the plaintiffs’ legal expenses.

Marijuana operators have raised concerns that the recent ruling has done away with most of the OCM’s regulations.

The case was brought forward by Leafly, a third-party marijuana promoter based in Seattle that runs a licensed marijuana store in upstate Rensselaer. Stage One dispensary and Rosanna St. John, one of its consumers, were also party to the lawsuit. In their filing, the plaintiffs claimed that the OCM prevented Stage One from working with Leafly to promote its marijuana products on the latter’s site.

In a statement, Leafly revealed that the company was pleased to hear that the court agreed with its claims. The promoter added that it was excited to support licensed retailers and consumers in New York with the firm’s full suite of services and products and noted that it hoped this decision would ultimately lead to a stable, healthy adult-use market in the state of New York.

In its statement, the marijuana promoter also highlighted the importance of offering consumers different choices as well as educational information when making purchasing decisions. It added that it was important that licensed retailers have equal access to crucial marketing and advertising tools that would allow them to succeed in this competitive landscape.

Governor Kathy Hochuk has yet to release a statement regarding the recent ruling. The governor, who oversees the OCM, has, however, initiated a review and possible overhaul of the office’s licensing and management.

Cannabis industry actors such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) are likely to welcome the court decision to reverse the ban on advertising marijuana products since such restrictions make it harder for state-legal cannabis businesses in the country to grow and sustain their operations.

Cresco Labs Inc. (CRLBF), closed Friday's trading session at $2, off by 6.9767%, on 1,216,995 volume. The average volume for the last 3 months is 722,890 and the stock's 52-week low/high is $1.00/$2.77.

Compass Minerals International Ltd. (CMP)

SmarTrend Newsletters, QualityStocks, MarketBeat, The Online Investor, DividendStocks, Daily Trade Alert, Trades Of The Day,, InvestorPlace, MiningNewsWire, The Street, Kiplinger Today, Zacks, StreetAuthority Daily, StreetInsider, Schaeffer's, All about trends, MarketClub Analysis, Barchart, BUYINS.NET, CRWEFinance, Daily Market Beat, Wyatt Investment Research, Daily Wealth, Top Pros' Top Picks, InsiderTrades, The Stock Dork and Insider Wealth Alert reported earlier on Compass Minerals International Ltd. (CMP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The smell of methane that pervades many dairy farms could be a thing of the past if a new system that uses microbes to convert methane into fertilizer is widely adopted. Windfall Bio is the startup behind this innovation. The company revealed that it completed a funding round that put $28 million in its hands to commercialize the production of these microbes.

It should be noted that this technique of converting methane into nitrogen fertilizer isn’t only applicable on farms. It can be deployed wherever methane accumulates, including landfills, oil wells or wetlands. The startup aimed at getting a novel way to deal with methane gas wherever it is found.

Why did Windfall Bio focus on methane? Currently, methane contributes approximately 30% to global warming. Additionally, this gas has the potential to warm the earth 86 times more than carbon dioxide during a 20-year window. Capturing this polluter could have a significant impact on slowing global warming.

Josh Silverman, CEO and cofounder of Windfall Bio, says the role of methane in fueling global warming doesn’t get as much attention as it should, and efforts to mitigate this driver of climate change aren’t funded in the same way that carbon dioxide-focused efforts are. The biochemist is convinced that Windfall Bio has found an affordable way to leverage the microorganisms found in soil to play a role in capturing methane in sustainable ways while producing fertilizers.

The company doesn’t modify the genes of the microbes in any way. Instead, it combines various kinds of methane-eating microbes in order to create a cocktail that packs a bigger punch in eating up any methane in the places where the microbes have been deposited. At a farm, for example, the farmer can direct a pipe from a covered lagoon of manure to a tank that contains the microbes.

The fertilizer produced as the microbes feed on the methane can then be applied to support plant growth. Windfall Bio says this fertilizer can be obtained at half the cost of conventionally produced nitrogen fertilizers. Farmers can also place the microbes directly in soil that has been overcultivated. However, this would be underusing those microbes because they work best when placed where methane pollution levels are high. However, adding them to soil would still help in placing nitrogen back into the soil.

If more methane is captured using these microbes, an additional benefit of greening the fertilizer industry would result because methane capture using microbes yields nitrogen fertilizers that can address the needs of farmers without relying on fossil fuels to make the needed fertilizers.

Given that the availability of conventional fertilizers from enterprises such as Compass Minerals International Ltd. (NYSE: CMP) is often subject to fluctuations resulting from various market forces, the nitrogen fertilizers made using microbes can be a timely stop-gap measure to ensure continuity of supply.

Compass Minerals International Ltd. (CMP), closed Friday's trading session at $14.3, off by 1.2431%, on 488,116 volume. The average volume for the last 3 months is 45.202M and the stock's 52-week low/high is $13.54/$39.78.

Rivian Automotive Inc. (RIVN)

InvestorPlace, Schaeffer's, The Street, QualityStocks, Kiplinger Today, MarketBeat, MarketClub Analysis, Early Bird, INO Market Report, StockEarnings, Investopedia, The Online Investor, Zacks, GreenCarStocks, Daily Trade Alert, AllPennyStocks, Louis Navellier, StocksEarning, The Night Owl, TipRanks, Trades Of The Day, InvestorIntel, DividendStocks, InvestorsUnderground, Cabot Wealth, BillionDollarClub, 360 Wall Street, FreeRealTime, Top Pros' Top Picks, Top Pros’ Top Picks and bullseyeoptiontrading reported earlier on Rivian Automotive Inc. (RIVN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Trust Point Inc. recently increased its stake in Rivian Automotive Inc. (NASDAQ: RIVN), purchasing more than 10,478 shares of the auto manufacturer’s stock. The total value of the recently purchased shares stands at $246,000. Trust Point is one of several institutional investors and hedge funds that have made changes to their positions in Rivian Automotive.

During the third quarter, Vanguard Group Inc. increased its stake in the electric vehicle manufacturer by 0.6%. After buying the additional 408,677 shares, the investment company now owns 63,845,364 shares of Rivian, with a total value of worth $1,550,165,000.

Morgan Stanley also raised its stake in Rivian by 14% in the third quarter, bringing the total number of shares it owns to 9,695,576. The shares now total a sum of $235,409,000. State Street Corp also increased its position in Rivian by almost 23% during the second quarter, adding 2,156,922 shares to its portfolio. Currently, the global financial services company owns 11,704,572 shares of the EV company’s stock, valued at $194,998,000.

BlackRock Inc. also raised its stake in the electric vehicle automaker by 2.9% in the first quarter, adding 1,443,514 shares to its portfolio. Currently, the multinational investment company owns 50,903,971 shares of Rivian’s stock, valued at $787,993,000. Additionally, Moneta Group Investment Advisors LLC bought a new position in Rivian Automotive in the fourth quarter worth roughly $228,175,000.

Hedge funds and institutional investors now own more than 66% of Rivian Automotive’s stock.

On Monday, Rivian’s stock opened at $10.10. The 50-day moving average for the company’s stock is $12.81 while its 200-day moving average stands at $16.76. Rivian Automotive has a market capitalization of $9.87 billion, with a debt-to-equity ratio of 0.48, a quick ration of 3.90 and a current ratio of 4.95. The automotive company issued its latest earnings result in February. In its report, its earnings per share for the quarter stood at $1.58.

Revenues for the quarter totalled $1.32 billion, which is slightly higher than the analyst estimate of $1.28 billion. On equity, the auto manufacturer had a negative return of 45.9% and a negative net margin of 122.5%.

Analysts on the sell-side expect that for the current fiscal year, the company will post -4.79 EPS.

In related news, Kjell Gruner sold nore than 19,000 of his Rivian shares in early March. The average share price at the time was $12.81, bringing the transaction’s total to $255,367. Following this transaction, Gruner now owns about 407,700 shares in Rivian, with a total value of $5,223,751.

Rivian Automotive Inc. (RIVN), closed Friday's trading session at $9.13, off by 4.5977%, on 57,909,457 volume. The average volume for the last 3 months is 24.336M and the stock's 52-week low/high is $9.08/$28.06.

Riot Blockchain Inc. (RIOT)

Schaeffer's, MarketClub Analysis, InvestorPlace, StocksEarning, QualityStocks, StockMarketWatch, INO Market Report, MarketBeat, Zacks, TradersPro, Market Intelligence Center Alert, The Street, The Online Investor, StockEarnings, Early Bird, Kiplinger Today, TraderPower, InvestorsUnderground, BUYINS.NET, AllPennyStocks, Trades Of The Day, Investment House, Daily Trade Alert, Penny Stock 101, Market Intelligence Center, BillionDollarClub, StreetAuthority Daily, PennyStockLocks, Trading Tips, The Wealth Report, StockRockandRoll, MarketMovingTrends, TopPennyStockMovers, CryptoCurrencyWire, DividendStocks, The Daily Market Alert, Money Morning, Inside Trading, Investors Alley, ProsperityPub, Jeff Clark Research, Promotion Stock Secrets, Louis Navellier and StreetInsider reported earlier on Riot Blockchain Inc. (RIOT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Brazil is gearing up for a significant shift in its approach to taxing cryptocurrencies. A fresh bill drafted by the Ministry of Finance is set to alter the taxation landscape for individual crypto investors. It aims to reclassify cryptocurrencies, subjecting them to taxation akin to capital instrument shares, considering their fluctuating exchange rates.

Under the forthcoming measure slated for presentation to the National Congress, cryptocurrency investors would be required to pay 15% of their earnings from cryptocurrency transactions as tax.

Currently, gains from cryptocurrencies are taxed as assets, with capital gains tax levied based on transaction volumes. This tax starts at 15% for transactions below 5 million reais ($990,000). For transactions exceeding 30 million reais (approximately $6 million), the tax rate increases to 22.5%, with scaled-down percentages for volumes falling in between.

The new taxation framework would encompass both non-fungible tokens (NFTs) and cryptocurrencies that investors trade on platforms which are registered and which conduct transactions surpassing 35,000 reais (around $7,000) every month. This threshold exceeds the minimum requirement for stocks, currently standing at 20,000 reais (approximately $4,000).

The primary objective behind the new measure is to foster fairness and precision in tax policies. It entails formalizing more rigorous criteria for identifying tax havens, including jurisdictions that maintain confidentiality regarding the ownership and shareholder information of foreign corporations operating in Brazil. This, in turn, will eliminate loopholes conducive to tax evasion. Brazilian law defines tax havens as countries taxing income at rates lower than 20%.

However, it remains uncertain whether the new measure will revise the old taxation thresholds, potentially exempting cryptocurrency investors from taxes on small cryptocurrency trades. The implementation of these legislative changes is slated for 2025, pending Congressional approval of the bill, which has been under development for more than a year.

This new tax system aligns with Brazil’s intensified scrutiny of the cryptocurrency sector. In February, Brazil’s cryptocurrency tax authority uncovered irregularities in more than 25,000 crypto tax declarations, employing a blend of artificial intelligence and traditional techniques for detection. Moreover, the measure forms part of the government’s broader initiative to restructure income taxes, initiated last year with the enactment of new regulations governing offshore and closed-end funds. The regulations created distinctions according to offshore entity ownership and residency.

A comprehensive bill overhauling income tax regulations for both individuals and corporations is anticipated to be presented to Congress at a later stage.

The tax policy changes in Brazil are likely to be of interest to crypto companies such as Riot Blockchain Inc. (NASDAQ: RIOT) since those new taxes could be the precursor of similar policies in other jurisdictions.

Riot Blockchain Inc. (RIOT), closed Friday's trading session at $9.1, off by 6.6667%, on 17,080,677 volume. The average volume for the last 3 months is 411,979 and the stock's 52-week low/high is $8.605/$20.65.

Verano Holdings Corp. (VRNOF)

QualityStocks, MarketBeat, InvestorPlace, The Street, Earnings360 and Early Bird reported earlier on Verano Holdings Corp. (VRNOF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Recently published data from a survey conducted in Washington State among teenagers and adolescents indicates a decline in both past-one-month and lifetime use of cannabis in the past few years, with notable decreases that have persisted through 2023. The findings suggest that the perceived accessibility of marijuana among minors has typically decreased since the state legalized recreational use in 2012, which contradicts concerns voiced by those opposed to legalization.

In 2023, about 8.4% of 10th graders in Washington reported using cannabis within the past month, a slight increase from 7.2% in 2021, according to the study. However, both figures were significantly lower than prelegalization statistics. For instance, in 2010, 20% of 10th graders admitted to using marijuana within the previous month.

Within King County, the most populated county in the state, only 5.5% of 10th graders reported marijuana use in the past 30 days in 2023, a decline from 7.3% in 2021 and a substantial decrease from 18.1% in 2010. Similar reductions were observed in lifetime cannabis use among students in other surveyed grade levels, including 12th, 8th and 6th grades.

In a recent blog post highlighted these findings, the state’s Liquor and Cannabis Board (LCB) indicated a stable trend in youth alcohol and marijuana use since 2021. Health officials credit the significant declines observed between the years 2018 and 2021 at least partially to the impact of the COVID-19 pandemic, although youth cannabis use had already been declining overall since the legalization of adult-use marijuana.

The state health department stated that while the long-term effects are uncertain, substance use remained relatively stable in 2023 in Washington and across the country. However, there were increases in the abuse of prescription medication, analgesics and other illicit substances compared to 2021, suggesting a need for more preventive measures.

Perceived marijuana access also decreased considerably, according to the study. In 2010, more than one-half of 10th graders surveyed said it would be easy to obtain the substance. However, by 2021, the number fell to 31.6%, and in 2023, this number further decreased to 30.8%.

The study also examined other marijuana-related attitudes and behaviors. Statewide, 10th graders were more likely in the past year to admit the risks of attempting or routinely consuming marijuana. Additionally, more respondents believed that youth using cannabis in their neighborhood would be apprehended by the police.

Even within peer groups, the acceptance of cannabis consumption has decreased compared to before recreational cannabis legalization. The majority of 10th graders now consider it wrong for someone their age to use cannabis.

These findings complement a recent study by the CDC that also utilized the Healthy Youth Survey and found a significant decrease in frequent and current cannabis use among teenagers in King County since the legalization of recreational marijuana in 2012. Researchers suggested that legalization and the associated regulations may have made marijuana less accessible to teens, although the COVID-19 pandemic could have also contributed to more declines.

Regarding the latest survey, the LCB expressed interest in understanding the prevalence of past-30-day cannabis use among 10th graders. A small percentage (9%) reported purchasing marijuana from a store or stealing (2%) it, which may indicate access to hemp-derived products outside of the licensed system.

The increasing number of studies confirming that cannabis legalization results in fewer teens accessing the substance confirms what industry actors such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) have always believed that ending prohibition can help in limiting access to marijuana by minors.

Verano Holdings Corp. (VRNOF), closed Friday's trading session at $5.07, off by 6.6298%, on 596,258 volume. The average volume for the last 3 months is 97 and the stock's 52-week low/high is $2.53/$7.08.

The QualityStocks Company Corner

Sigyn Therapeutics Inc. (OTCQB: SIGY)

The QualityStocks Daily Newsletter would like to spotlightFathom Sigyn Therapeutics Inc. (OTCQB: SIGY).

Sigyn Therapeutics (OTCQB: SIGY), a medical technology that creates medical solutions to treat life-threatening conditions, is developing a portfolio of technologies, including Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM) and ImmunePrep(TM), which have each been designed to overcome a current limitation in healthcare. "As it relates to pathogen-associated disorders, the company has advanced Sigyn Therapy(TM) from concept through product development and subsequently completed five invitro blood purification studies, which validated the ability of Sigyn Therapy(TM) to extract 12 different therapeutic targets from human blood plasma. As a result of these study outcomes, Sigyn Therapy is a candidate to treat a wide range of pathogen-associated disorders that are not addressed with drug therapies. The company also completed animal studies at the University of Michigan and then collaborated with a leading dialysis organization to establish the treatment protocol, site locations and principal investigators for first-in-human studies of Sigyn Therapy," a recent article reads. "We believe Sigyn Therapy has an unprecedented capability to simultaneously clear deadly inflammatory mediators and pathogenic sources of life-threatening inflammation from human blood," Sigyn Therapeutics CEO Jim Joyce is quoted as saying.

To view the full article, visit

Sigyn Therapeutics Inc. (OTCQB: SIGY) is a development-stage medical technology company headquartered in San Diego, California. The company’s therapeutic candidates include Sigyn Therapy™ to address pathogen-associated inflammatory disorders, the ImmunePrep™ platform to enhance the performance of immunotherapeutic antibodies, ChemoPrep™ to improve the delivery of cancer chemotherapy and ChemoPure™ to reduce the toxicity of chemotherapy.

Sigyn created each of these technologies with two prerequisites in mind: 1) they must offer to overcome a clearly defined limitation in healthcare, and 2) their successful clinical advancement would offer a potential competitive advantage to established therapeutic organizations.

Sigyn Therapy™

The company is advancing Sigyn Therapy™ to treat pathogen-associated inflammatory disorders that are not addressed with FDA approved drugs. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia and sepsis, which is the leading cause of hospital deaths in the United States.

The technology has the following attributes and capabilities.

  • Sigyn Therapy™ incorporates a formulation of adsorbent components that have more than 200,000 square meters (~50 acres) of surface area on which to adsorb and remove therapeutic targets from the bloodstream.
  • In vitro studies have demonstrated the ability of Sigyn Therapy™ to eliminate life-threatening pathogen and inflammatory disease targets from human blood plasma. In these studies, 12 relevant targets, including viral pathogens, bacterial toxins and inflammatory cytokines, were validated. Subsequent animal studies were completed at the University of Michigan.
  • Sigyn Therapy™ is highly efficient, as the entire circulatory system of a patient can pass through the device ~15-times during a four-hour treatment.
  • To allow for broad deployment, Sigyn Therapy™ is designed for use on the established infrastructure of dialysis and continuous renal replacement machines already located in hospitals and clinics around the world.

First-in-human studies of Sigyn Therapy™ plan to enroll dialysis dependent end-stage renal disease (ESRD) patients with endotoxemia and concurrent inflammation, which are highly prevalent and associated with increased mortality in the ESRD population. There are more than 550,000 individuals with ESRD in the United States, which result in approximately 85 million dialysis treatments being administered each year.

The ImmunePrep™ Platform

Immunotherapeutic antibodies to treat cancer are among the most valued assets in global medicine. However, these drugs suffer from a severe limitation: they are poorly delivered to cancer cell targets, and, as a result, a majority of patients do not respond to therapy.

The Sigyn team recognized that just a small fraction of an antibody dose reaches its cancer cell target, yet a significant portion of the same dose can be sequestered by circulating decoys that display the target (antigen) binding site of the antibody. In response, Sigyn designed the ImmunePrep™ platform to leverage the use of therapeutic antibodies to create extracorporeal blood purification devices that sweep antibody decoys from the bloodstream prior to the subsequent infusion (normal delivery) of the same therapeutic antibody.

The company believes its reverse decoy mechanism will increase the availability of antibodies to interact with their intended disease targets, and, simultaneously, the devices will also extract disease targets from the bloodstream to further improve patient benefit.

The opportunity to enhance the performance of therapeutic antibodies is significant. Consider that Pfizer’s $43 billion acquisition of Seagen Inc. and Amgen’s $27.8 billion acquisition of Horizon Therapeutics were the highest valued M&A deals of 2023. In both cases, transaction values were driven by market-cleared antibody assets.

Perhaps more revealing were the values placed on clinical-stage (pre-revenue) therapeutic antibody candidates. In this regard, consider Merck’s $10.8 billion acquisition of Prometheus Biosciences and Roche’s $7 billion acquisition of a clinical-stage antibody from Roivant Sciences.

In the backdrop of these M&A transactions, the immune checkpoint antibody Keytruda (Merck) became the world’s best-selling (non-vaccine) drug in 2023, with anticipated revenues of ~$24 billion.

ChemoPrep™ and ChemoPure™

Recent scientific publications have reported that only 1% of chemotherapy is delivered to the tumor cell targets of cancer patients. In response, the Sigyn team designed ChemoPrep™ to overcome a delivery limitation of the most commonly administered drug to treat cancer.

The company is developing ChemoPrep™ to reduce the circulating presence of tumor-derived exosomes (tumor exosomes), which interfere with chemotherapy delivery. High concentrations of tumor exosomes in the bloodstream correspond with poor treatment outcomes, whereas low concentrations of tumor exosomes correspond with more favorable outcomes. As compared to non-cancer subjects, exosome populations are reported to be 10x to 500x higher in the bloodstream of cancer patients. Based on these factors, the company believes there is a compelling scientific rationale to reduce the circulating presence of tumor exosomes prior to chemotherapy administration.

Inversely, the Sigyn team recognized that if 99% of chemotherapy was missing its target, then there was a need to eliminate off-target chemotherapy from the bloodstream to reduce toxicity and limit organ damage. This factor led to the design of ChemoPure™ to reduce treatment toxicity by reducing the presence of off-target chemotherapy from the bloodstream. The company believes that a reduction in chemotoxicity may also alleviate treatment-related fatigue and potentially temper the long-term health consequences associated with chemotherapy administration.

Management Team

James A. Joyce is Co-Founder, Chairman and CEO of Sigyn Therapeutics. He has more than two decades of public company CEO and corporate board leadership experience and is an inventor or co-inventor of 20 pending or issued patents, including those underlying ImmunePrep, ChemoPrep, ChemoPure and Sigyn Therapy. Previously, he was founder and CEO of Aethlon Medical, a therapeutic technology company that he built from a start-up to a Nasdaq-traded company. Under his leadership, Aethlon developed the first medical device to receive two breakthrough device designations from the FDA. Mr. Joyce graduated from the University of Maryland.

Annette Marleau, Ph.D., is Chief Scientific Officer at Sigyn Therapeutics. Prior to joining the company, she was Chief Technology Officer at Immunicom Inc. and Director of Research at Aethlon Medical Inc. Additionally, she is an inventor on pending and issued patents underlying blood purification therapies targeting cancer, inflammatory disorders and life-threatening infectious diseases. She holds a Ph.D. from Western University, an M.S. from the University of Guelph and a B.S. from the University of Waterloo in Canada.

Jerry DeCiccio, CPA, is CFO at Sigyn Therapeutics. He has more than 40 years of financial industry experience. Previously, he was CFO/COO at Intech Electromechanical, CFO/COO at GTC Telecom, CFO at Incomnet Communications and President at Cerebain Biotech Corp. He also served in senior financial roles at Parker Hannifin Corp., Waste Management Inc. and Newport Corp. He earned a bachelor’s degree in accounting and business administration from Loma Linda University and an MBA in finance and systems technology from the University of Southern California.

Sigyn Therapeutics Inc. (OTCQB: SIGY), closed Friday's trading session at $6, up 9.0909%, on 200 volume. The average volume for the last 3 months is 24,870 and the stock's 52-week low/high is $2.08/$12.80.

Recent News

Turbo Energy S.A. (NASDAQ: TURB)

The QualityStocks Daily Newsletter would like to spotlight Turbo Energy S.A. (NASDAQ: TURB).

Turbo Energy (NASDAQ: TURB), a photovoltaic energy company based in Spain, is strongly positioned to capitalize on the growing demand for photovoltaic energy storage systems in the European Union with its patented Sunbox, an AI-powered solution for home and commercial photovoltaic installation. "Following the recent acquisition of an international patent, Turbo Energy is now strategically determining the countries for registration. ‘The result will be a unique energy storage solution that we believe will provide Turbo a leading position in this industry worldwide and help pave the way towards a more sustainable and energy-efficient future,' stated Turbo," a recent article reads. "Sunbox helps EU policymakers meet environmental goals while incentivizing consumers through lowered energy costs, maximized efficiency, and price shock protection. The system provides a comprehensive and intelligent energy management solution, utilizing AI algorithms to optimize energy usage while ensuring a reliable power supply. Additionally, the integration of an electric vehicle charger enables seamless charging at home and increased reliability on the road."

To view the full article, visit

Turbo Energy S.A. (NASDAQ: TURB) designs, develops and distributes equipment for the generation, management and storage of photovoltaic energy in Spain, Europe and internationally.

Turbo Energy’s products include lithium-ion batteries and inverters. Additionally, the company recently launched its flagship product, the Sunbox, an all-in-one device that integrates most of the equipment required for a residential photovoltaic installation. The Sunbox is powered by AI and features a software system that monitors the generation, use and management of photovoltaic energy by analyzing large amounts of data related to energy generation, consumption, market prices and weather forecasts. This AI system optimizes battery usage, reducing electricity bills and providing peak-use reduction and uninterruptible power supply functions.

Turbo Energy currently sells its photovoltaic energy equipment primarily through distributors for residential consumers in Spain, but it possesses the expertise and international perspective to expand its product portfolio into industrial and commercial scale and markets, as well as advancing the internationalization process it has already started. The company plans to expand into the industrial photovoltaic sector with its new Sunbox, launched in 2023, in higher power and capacity variants. Its goal is to become a significant player in this sector and contribute to the growth of renewable energy solutions.

The company was incorporated in 2013 and is based in Valencia, Spain. It operates as a subsidiary of Umbrella Solar Investment S.A.


Lithium-Ion Batteries

Turbo Energy is one of the leading companies that introduced lithium-ion batteries for photovoltaic energy storage in Spain. Primarily for the home energy storage market, the company’s batteries have capacities from 2.24 kWh to 5.1 kWh in 24 and 48 volts. In addition, its 48V / 5.1 kWh units are available in a dual battery system.


The inverter converts the direct current produced by the photovoltaic panels into alternating current that can be used by household appliances. It also regulates battery charging and discharging based on energy needs and optimizes utilization of generated renewable energy. Turbo Energy currently offers multiple models that cover most household installations.

All-in-One Sunbox

This product incorporates inverters, batteries and the rest of the components necessary to operate and protect the photovoltaic installation. This saves installation cost and assembly and configuration time while preventing errors. Notably, the latest Sunbox models also offer an EV charging option.

Software System

In communication with the inverter, the company’s software monitors energy flows between the photovoltaic panels, household consumption, storage and an optional electric vehicle charging station. The software allows users to customize an automatic backup mode based on weather forecasts, or manually select which part of the battery will be reserved for possible power outages. It also allows the battery to be used in a peak shaving mode, which leverages AI to trigger battery power when grid energy is most expensive, effectively reducing the amount of high-cost power drawn from the grid.

Market Opportunity

According to a report by Fortune Business Insights, a global research and reporting firm, the solar energy storage battery market was estimated to be worth $3.33 billion in 2022 and is projected to reach a value of more than $20 billion by 2030, marking a CAGR of 24.2% over the forecast period.

These batteries are crucial components of renewable energy systems, allowing for the storage of excess electricity generated by solar panels, so it can be used during times of no or low sunlight. By storing energy and supplying it when needed, these batteries reduce reliance on the power grid and maximize self-consumption while helping users avoid peak electricity rates. They also contribute to the transition toward a cleaner and more sustainable energy future by enabling residential consumers and businesses to use solar power even when the sun is not shining.

Management Team

Enrique Selva Bellvís is the CEO and founder of the Umbrella Group. In addition, he serves as vice-president of the Valencian Association of Energy Sector Companies industry group. Before his career in the solar energy sector, he was the founder and CEO of Innova Ingenieros Consultores. He holds a degree in industrial engineering with a specialization in energy from the Polytechnic University of Valencia and completed the Management Development Programme at the IESE Business School.

Mariano Soria is the Chief Innovation Officer for the Umbrella Group and serves as General Manager of Turbo Energy. He was CEO of Punt Moble XXI S.L. and continues to serve on that company’s board. Before that, he was the General Manager of REJMAR S.A., a land development company. He received his degree in industrial engineering and industrial organization from the Polytechnic University of Valencia, and his MBA from the European University of Madrid.

Alejandro Moragues is CFO of Turbo Energy. Previously, he held the position of Senior Corporate Auditor for U.S. company Euronet Worldwide Inc. and was an external auditor for PricewaterhouseCoopers. He holds a bachelor’s degree in business administration and management from the Polytechnic University of Valencia.

Manuel Cercos is Chief Commercial Officer at Turbo Energy. Previously, he held positions at Técnicas Aplicadas en Baterías S.L., where he served as Sales Director and Sales Manager. Before that, he worked as a Sales Technician at DAISA.

Turbo Energy S.A. (NASDAQ: TURB), closed Friday's trading session at $1.19, up 4.3768%, on 3,285 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $12.80/$.

Recent News

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has completed the execution of three pivotal registration/validation batches of PAX-101, which is an IV formulation of suramin. According to the announcement, this is an important milestone achievement as the company works toward enabling a New Drug Application ("NDA") submission to the U.S. Food and Drug Administration ("FDA"). Currently, the company anticipates submitting the NDA in Q4 2024; this will mark another key milestone as the company works toward the potential commercial availability in the United States of the first and only form of suramin for the treatment of Stage 1 Human African Trypanosomiasis ("HAT"). "This is a very significant milestone for PaxMedica as it endeavors to move PAX-101 towards an NDA submission," said PaxMedica chair and CEO Howard Weisman in the press release. "The long-term vision for PaxMedica is to further clinical investigation of PAX-101 as a treatment for individuals who struggle with autism spectrum disorder. With this important manufacturing milestone completed, we have removed a major impediment to testing PAX-101 as a treatment for the core symptoms of autism spectrum disorder. This also progresses us towards our goal of being able to be a consistent and reliable global source of this lifesaving drug for the treatment of HAT currently listed as one of the World's Essential Medicines. It is our goal to ultimately conduct clinical trials for the use of PAX-101 in the treatment of the core symptoms of Autism Spectrum Disorder. There are currently no approved medications for the core symptoms Autism Spectrum Disorder."

To view the full press release, visit

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Friday's trading session at $0.839, up 103.7149%, on 114,294,741 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.372/$38.9283.

Recent News

Zoned Properties Inc. (OTCQB: ZDPY)

The QualityStocks Daily Newsletter would like to spotlightFathom Zoned Properties Inc. (OTCQB: ZDPY).

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company for emerging and highly regulated industries, is focusing on seizing direct-to-consumer real estate opportunities in the rapidly growing and regulated cannabis market. This is amid changing regulations and attitudes towards cannabis use, which are transforming the industry. "Cannabis businesses are expanding significantly as regulations evolve, leading to an increased demand for specialized, direct-to-consumer properties that include dispensaries, manufacturing or processing centers, and distribution hubs. Real estate investors are capitalizing on this demand by acquiring properties for rental income generation while potentially realizing significant property value appreciation as the industry grows," a recent article reads. "In alignment with the evolving market, ZDPY has recently secured and acquired investment properties in Michigan, Arizona and Illinois. All properties in ZDPY's portfolio boast 100% occupancy and a weighted average lease term of 10+ years. Each leased property is occupied by a commercial cannabis tenant, and the company anticipates more than $2.5 million from its property investment portfolio in 2024. Zoned Properties Brokerage has closed over $80 million of commercial real estate deals nationally since 2021… ZDPY is also leveraging digital innovation through its proprietary cannabis technology platform, called REZONE. Similar endeavors have leveraged data-driven insights, analytics and artificial intelligence to identify potential investment properties, streamline processes and enhance efficiency."

To view the full article, visit

Zoned Properties Inc. (OTCQB: ZDPY) is a technology-driven property investment company focused on acquiring value-add real estate within the regulated cannabis industry in the United States. The company aspires to innovate within the real estate development sector, focusing on direct-to-consumer real estate that is leased to best-in-class cannabis retailers.

The company is redefining the approach to commercial real estate investment through its standardized investment process backed by its proprietary property technology. Zoned Properties has developed a national ecosystem of real estate services to support its real estate development process, including a commercial real estate brokerage and a real estate advisory practice.

With a decade of national experience and a team of experts devoted to the emerging cannabis industry, Zoned Properties is addressing the specific needs of a modern market in highly regulated industries. The company targets commercial properties that face unique zoning or development challenges, identifies solutions that can potentially have a major impact on their commercial value and then works to acquire the properties while securing long-term, absolute-net leases.

Zoned Properties targets commercial properties that can be acquired and rezoned for specific purposes, including the regulated and legalized cannabis industry. It does not grow, harvest, sell or distribute cannabis or any substances regulated under United States law.

The company is headquartered in Scottsdale, Arizona.


The company’s investment properties are located in Arizona, Michigan and Illinois, with 100% occupancy and a weighted average lease term over 10 years. Each of the company’s leased properties is occupied by a commercial cannabis tenant. The company is expecting rental revenue from its property investment portfolio of greater than $2.5 million in calendar-year 2024.

Zoned Properties maintains a portfolio of properties that it owns, develops and leases. As of February 2024, the company leases land and/or building space at the six properties in its portfolio to licensed and regulated cannabis tenants in areas with established cannabis regulations and zoning procedures. Four of the leased properties are zoned and permitted as regulated cannabis retail dispensaries, and two of the leased properties are zoned and permitted as regulated cannabis cultivation and processing facilities.

The company considers the two cultivation sites in its portfolio as legacy properties and may consider selling or leveraging those properties to unlock equity and create capital availability in the future. The Zoned Properties investment thesis has evolved over the years as the cannabis industry has emerged, and the company is currently focused on investing capital into direct-to-consumer properties, located in state-markets with robust cannabis consumer demand in the industry.

Zoned Properties is in pursuit of property acquisitions that can be characterized as consumer-facing, retail dispensary properties that are positioned to be leased to retail dispensary cannabis tenants under net leasing structures. As of September 2023, the company has agreements in place to acquire new investment properties with new cannabis tenants located in Arizona, Missouri and Illinois. The company plans to initiate and target its investment process in Ohio and Maryland.

With a strategic shift in focus to direct-to-consumer real estate that is leased to best-in-class cannabis retailers in the industry, the company will continue to utilize its competitive edge when identifying excellent investment properties. Zoned Properties has a full pipeline of acquisition prospects and continues to utilize an extremely disciplined capital allocation approach.

Market Opportunity

According to MJBizDaily, a publication that has covered the North American cannabis business since 2011, combined U.S. medical and recreational cannabis sales were estimated at approximately $33.6 billion at the end of 2023, largely driven by the opening of new adult-use markets.

The publication projects that combined U.S. retail cannabis sales will reach upwards of $53.5 billion by 2027, according to an analysis published in its volume of cannabis market research, the MJBiz Factbook.

As of February 2024, 38 U.S. states had legalized medical, recreational or other limited use of cannabis. The Pew Research Center reports that, in January 2023, there were more than 11,000 licensed cannabis dispensaries in the U.S. In addition, global research firm IBISWorld reports that more than 40,000 U.S. localities have adopted regulations governing cannabis usage, production, processing and/or dispensing.

Management Team

Bryan McLaren is the Chairman and CEO of Zoned Properties. Previously, he worked as a Sustainability Consultant for Waste Management Inc., where he led the strategic development and operational implementation of zero-waste programs for clients. He was also appointed as a city Sustainability Commissioner. He holds a bachelor’s degree in business administration from the University of San Diego, a master’s degree in sustainable development from Northern Arizona University, an executive master’s degree in business leadership from Arizona State and an MBA with a specialty in sustainable development.

Berekk Blackwell is the President and COO of Zoned Properties. He previously spent time in developing domestic and international markets for Kahala Brands, a conglomerate of over 15 QSR franchises, including Cold Stone Creamery and Blimpie Subs. He later worked on developing QSR concepts for Revamp Corp. in Tokyo. After returning to the U.S., he served as president of Daily Jam, a limited-service breakfast and brunch chain. He holds a bachelor’s degree in business administration in finance from Fort Lewis College.

Patrick Moroney is the Director of Real Estate Acquisitions for Zoned Properties. Previously, he was one of the most successful Associate Brokers at Kidder-Mathews, focusing primarily on the regulated cannabis industry. He also worked as a commercial real estate broker rep at Cushman & Wakefield and Colliers International. He graduated from Arizona State University, after which he spent four years as a local sports broadcaster in Georgia and Iowa.

Kyle Gere is the Director of Advisory Services at Zoned Properties. He has years of licensing experience across multiple U.S. states in the medical and recreational cannabis markets. Since 2015, he has been involved in cannabis real estate transactions in Arizona and Michigan, managing a portfolio of medical marijuana properties. He attended Northern Arizona University, graduating with a bachelor’s degree in business administration in both management and marketing.

Zoned Properties Inc. (OTCQB: ZDPY), closed Friday's trading session at $0.517, up 0.407846%, on 63,578 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.35/$0.80.

Recent News

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

Pancreatic cancer is a challenging cancer to treat. Research shows that roughly 12% of individuals diagnosed with this particular cancer live beyond five years. Additionally, treatments such as chemotherapy, immunotherapy and targeted therapies are unsuccessful in treating pancreatic cancer. Prior research has determined that combined PD1-inhibitors and chemotherapy hasn't brought any improvements in pancreatic cancer patients. PD1-inhibitors are an immunotherapy drug that assists the immune system in recognizing and eliminating cancer cells effectively. As more companies such as Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) invest in developing immunotherapies targeting different malignancies, patients diagnosed with many forms of cancer could receive immunotherapy as a viable treatment option. This would be in contrast to the current situation where only a fraction of cancer patients are deemed suitable to undergo immunotherapy.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Friday's trading session at $0.48, even for the day, on 6,952 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.45/$2.44.

Recent News

Coyuchi Inc.

The QualityStocks Daily Newsletter would like to spotlight Coyuchi Inc.

European bankers are pushing back against the increasingly strict environmental, social and governance ("ESG") reporting requirements being passed in the European Union, yet their competitors in America aren't required to adhere to those requirements. The European Banking Federation ("EBF") recently said that as long as Wall Street continues to ignore ESG rules, European lenders who adhere to American ESG rules will find it impossible to compete with their U.S. counterparts. ESG has been one of the largest trends in the financial sector for the past several years, partly due to being pushed by major investment companies, such as BlackRock, and the deafening call for greater corporate accountability and sustainability. According to these requirements, companies have to continually enhance their ESG reporting to show how their corporate activities harm the environment and community as well as the steps they have taken to mitigate their effect on surrounding communities. While bankers in Europe are pushing back against ESG investment guidelines, individual companies such as Coyuchi Inc. in North America are marking themselves as entities that personify sustainability in their entire value chain, a practice that is winning over customers.

Coyuchi is the gold standard in sustainable luxury home goods. The company offers sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. With a timeless, coastal-inspired aesthetic, Coyuchi uses only 100% organic cotton materials to manufacture all of its textiles.

The Company was built upon four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. These guiding principles have proven an effective market strategy. In 2021, Coyuchi earned $33.3 million in net sales, amounting to 26% YoY growth (the industry average is only 5%). It also experienced 2x customer growth to 200,000 active customers, averaging a 35% customer repeat purchase rate.

With a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base that drives the fast-growing organic luxury market, Coyuchi is prepared to propel a new phase of growth as the rest of the world finally awakens to sustainability at scale.

A Lucrative Market Ripe for the Taking

The global market for organic bedding, which was estimated at $814.3 million in 2020, is projected to reach $1.1 billion by 2027, growing at a CAGR of 4.9% over that period, according to Research and Markets. More specifically, the domestic organic bedding market is estimated at $240.1 million in 2020, according to Statista. Overall, the U.S. market for home textiles is currently valued at $25 billion annually, and, with a forecast annual growth rate of 5%, it is expected to reach $30 billion by the end of 2025.

Grand View Research reported in 2020 that shifting consumer preference toward high-end lifestyle products is a key factor driving the growth of the organic bedding market. Seventy-four percent of consumers are willing to pay more for sustainable products – a consumer preference that has steadily increased over the last few decades. Millennials especially favor ethical consumption over price when purchasing goods and services, with 83% of millennials reporting that they want the brands they purchase from to align with their beliefs and values ( With a majority millennial customer base, Coyuchi is poised to capitalize on this trend.

Industry Defining Sustainability Practices

For 30 years, Coyuchi has explored organic farming and sustainable textiles and guarantees the highest environmental and ethical standards through a number of certifications such as The Global Organic Textile Standard (GOTS), Fair Trade Certified, and MADE SAFE®.

Coyuchi continues to push the organic textile market forward through its circularity initiatives and by supporting cross-industry sustainability advocates. Coyuchi’s mission to bring beauty and comfort to every home without sacrificing the health of our planet has resulted in a number of important sustainability checks and balances.

  • A Circular Business Model: Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change with its take back and recycling program, 2nd Home™. In 2017, it became the first luxury home brand to implement such an initiative, and, since then, the company has eliminated 68,758 lbs. of toxic chemicals from homes and renewed 6,000 lbs. of textiles.
  • The Coyuchi Climate Council: In early 2022, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.
  • C4: The California Cotton & Climate Coalition: Most recently, Coyuchi announced it is a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. Working together pre-competitively, C4 creates a structure for investing in regionally grown, Climate Beneficial™ cotton and directly supports the livelihoods of the farmers that grew it. Coyuchi is the only home industry brand currently involved in the project.

Omnichannel Business Model

Coyuchi differentiates itself through an omnichannel and circular business model, both of which have proven a clear draw for customers. It was an early adopter of an e-commerce sales and marketing approach (over 80% of its sales are directly through, creating a distinct advantage over incumbents and start-up newcomers in the luxury space. This has resulted in a high lifetime value customer, luxury retail partners such as Nordstrom, and a flagship store in Marin County.

Coyuchi’s Organic Textile Products

Coyuchi’s product assortment consists of consciously designed bedding, bath, apparel, and lifestyle products spread across about 1,400 SKUs. The company believes that its product assortment, produced from 100% organic cotton with Global Organic Textile Standard (GOTS) certification, provides it with a significant competitive advantage. GOTS is the world’s leading textile processing standard for organic fibers, ensuring the organic status of textiles after harvesting raw materials through environmentally and socially responsible manufacturing all the way to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi’s focused product assortment consists of four core categories:

  • Bedding – A full suite of sustainable, organic, and high-quality sheets, duvet covers, blankets, and throws.
  • Bath – A luxurious line of towels, bath rugs, and mats.
  • Apparel – Premium apparel for men and women, including robes, sweaters, pants, and pajamas.
  • Lifestyle – The lifestyle category offers 135 SKUs, from organic napkins to crossbody totes.

Management Team

Eileen Mockus is President and CEO at Coyuchi. She has more than 25 years of experience in retail, having held positions in textile development at Patagonia, Pottery Barn Teen, and The North Face. She earned a bachelor’s degree in textiles and clothing from UC Davis and an MSBA from San Francisco State University.
Sejal Solanki is Chief Marketing Officer at Coyuchi. She previously served as the company’s Vice President of E-Commerce. Before joining Coyuchi, she worked at teen clothing giant Charlotte Russe. She oversees the company’s digital marketing, site experience, brand marketing, and e-commerce strategy.

Marcus Chung is Coyuchi’s COO, overseeing supply chain, sourcing strategy, sustainability, and IT. He previously held positions at notable direct-to-consumer brands Third Love and Stitch Fix, as well as national retailer The Children’s Place. He holds a bachelor’s degree from Wesleyan University and an MBA from UC Berkeley’s Haas School of Business.

Margot Lyons is Director of Sustainability and Sourcing at Coyuchi, where she works with strategic partners to ensure all the company’s product sustainability standards are met. She received a master’s degree in textiles and clothing from UC Davis.

Use of Proceeds

This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence, and B2B strategic partnerships with wholesalers, and online marketplaces.

Recent News


Bravo Multinational Inc. (OTC: BRVO)

The QualityStocks Daily Newsletter would like to spotlightFathom Bravo Multinational Inc. (OTC: BRVO).

Bravo (OTC: BRVO) is a company actively exploring opportunities in the entertainment, hospitality and technology sectors to generate long-term value for its shareholders through high-growth business ventures. "Bravo recently announced entering into an asset purchase agreement to acquire the assets of Streaming TVEE Inc., marking its entrance into the video streaming market… The company's new streaming service, TVee NOW(TM), intends to offer linear TV, also known as traditional broadcast television, which uses cable and satellite networks through a joint venture with a third party. The joint venture is expected to close at a later date. The streaming platform will also offer an array of on-demand content, including but not limited to movies, series/shows, concerts, comedy specials, events, and more – all at no or low cost to its viewers. TVee NOW also plans to supplement its own original and exclusive content," a recent article reads. "The asset purchase agreement with Streaming TVEE includes acquiring the license of OTT (over-the-top) streaming technology, which is a hybrid model consisting of advertising-based video-on-demand (‘AVOD'), utilizing programmatic advertising through ad servers, and subscription-based video-on-demand (‘SVOD'), which Bravo plans to offer at competitive rates compared to other services."

To view the full article, visit

Bravo Multinational Inc. (OTC: BRVO) actively explores opportunities in the entertainment, hospitality and technology sectors to generate long-term value for its shareholders through high-growth business ventures. Currently focused on pioneering innovative solutions in the digital content landscape, the company’s goal is to provide cutting-edge and diverse content experiences to a global audience.

In February 2024, Bravo finalized a deal to acquire Streaming TVEE Inc.’s assets, marking a pivotal step in establishing its flagship offering, aptly named TVee NOW™. The acquired assets provide the company with the technology and foundation to soon offer streaming services including Video-On-Demand (VOD) and linear TV, often referred to as traditional broadcast TV, which encompasses cable and satellite networks, through a joint venture with Pythia Experiences.

TVee NOW™ plans to offer a wide range of on-demand content, including movies, series, concerts and original programming, at minimal or no cost to viewers. The service, set for beta launch in Q1 2024, will be accessible across various devices, with dedicated apps available on platforms such as Roku, Apple and Google Play stores, reinforcing Bravo’s commitment to innovation and audience accessibility.

The company is based in Virginia Beach, Virginia, with a second office soon opening in Las Vegas, Nevada.


TVee NOW’s streaming service will offer a portion of its content for free, catering to the growing demographic of cord-cutters and aligning with the dynamic landscape of advertising-based video on demand (AVOD) streaming. Bravo’s Over-The-Top (OTT) streaming platform is specifically crafted to deliver content directly to viewers via the internet, accessible through a browser or freely downloadable apps on smartphones, tablets and smart TVs.

Bravo’s planned strategic approach for content is to first integrate partnered Free Ad-Supported TV (FAST) channels, programmatic advertising and a tiered revenue sharing model. Additionally, the company plans to complete the deal with Pythia Experiences, enabling a hybrid model comprised of AVOD, utilizing programmatic advertising through ad servers, and Subscription-based Video-on-Demand (SVOD), which the company plans to offer at competitive rates compared to other services. With this model completed, Bravo can bridge the gap until the company can ultimately create its own original content.

Through the asset purchase agreement with Streaming TVEE, Inc., the company obtained exclusive rights, image and likeness, label waivers and exploitation rights for streaming of 117 high-definition music and comedy performances, each offering a director’s cut and multiple camera perspectives. Some of the music artists include Snoop Dogg, H.E.R., Kings of Leon, Alicia Keys and Bone Thugs-N-Harmony, along with comedic performances from Bill Burr, Jim Gaffigan, Kristen Schaal, Rob Delaney and others. This original footage will allow Bravo to recreate shows in diverse formats, which can showcase these concert films in a compelling full-feature format.

Market Opportunity

A report from Fortune Business Insights, a global market research and reporting firm, estimated the global video streaming market at $455.45 billion in 2022. It is projected to grow from $554.33 billion in 2023 to $1.9 trillion by 2030, achieving a CAGR of 19.3% during the forecast period.

Growth drivers, according to the report, include a rising number of users of Video-on-Demand services (YouTube, for example) worldwide and the growing adoption of OTT content providers (like Netflix and Hulu, among many others) by consumers, as well as consumers’ willingness to spend more for streaming video content.

Management Team

Grant Cramer is CEO and Director of Bravo. He has more than 30 years of experience as an actor, writer, director, producer and production executive. As founder and president of Landafar Entertainment and Global Pictures Media, he has overseen development and production of 14 feature films. He executive produced Lone Survivor, November Man and Arctic Dogs. He produced And So It Goes, directed by Rob Reiner and starring Michael Douglas and Diane Keaton. His short film Say Goodnight, Michael won several awards, including the Grand Jury Award at the New York International Independent Film Festival.

Frank Hagan is Bravo’s President and Director. He is an Emmy-nominated producer with over 30 years of experience in the entertainment industry. He is the former Programming Director and GM of QTN. He has produced shows for major networks and companies, including Discovery Channel, History Channel and Relativity Media. Most recently, he served as a consulting producer for Electric Entertainment’s ElectricNOW! and the Saturn Awards and worked as a regular weekly panelist for Outlaw Internet Radio.

Richard Kaiser is CFO and Director of Bravo. He is also CFO at BioForce Nanosciences Holdings Inc. and Gold Rock Holdings Inc. He serves on the board of Element Global Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings Inc. He previously directed investor relations for Royal Standard Minerals Inc. and Scorpio Mining Inc. He was also Head of Corporate Communication and Investor Relations at Air Packaging Technologies Inc. and Puff Pack Industries Inc.

Kayla Slick is COO and Director at Bravo. She has more than 15 years of experience in various industries, including finance, healthcare, technology, retail, hospitality and entertainment. She co-founded The PRIME Symposium and significantly increased revenues for INSIDE Public Accounting. She held positions at Interactive Digital Solutions, where she founded the Sales Development Program and was later promoted to Marketing Communications Director for IDS’ flagship virtual patient observation product.

Bravo Multinational Inc. (OTC: BRVO), closed Friday's trading session at $0.23, even for the day, on 1,056 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.068/$0.95.

Recent News

Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome ("HLHS"), Alzheimer's disease and Aging-Related Frailty, has closed on its previously announced public offering. The offering was comprised of up to 2,234,043 shares of Class A LGVN common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 2,234,043 shares of Class A common stock, both offered at $2.35 per share and associated warrant. The announcement noted that the warrants are exercisable upon issuance for up to five years. The public offering resulted in gross proceeds of approximately $5.2 million before standard deduction of fees and other expenses. According to the announcement, Longeveron plans to use the funds for ongoing clinical and regulatory development of Lomecel-B(TM), the company's proprietary treatment for several disease states and indications, including HLHS and Alzheimer's disease; the company may also use the funds for obtaining regulatory approvals, capital expenditures, working capital and other general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

To view the full press release, visit

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.


Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Friday's trading session at $1.69, off by 16.3366%, on 519,012 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.62/$44.00.

Recent News

SUIC Worldwide Holdings Ltd. (OTC: SUIC)

The QualityStocks Daily Newsletter would like to spotlightFathom SUIC Worldwide Holdings Ltd. (OTC: SUIC) .

BD Bankers is working on financing up to $100 million in Intellectual Property ("IP") and equipment lending intended to integrate advanced systems and fintech patents held by the company

The company will facilitate B2B financing for its merchants, supporting their advancement in B2B technology by utilizing IP lending financing

The global supply chain finance market was valued at $6 billion in 2021. It is projected to reach $13.4 billion by 2031, growing at a CAGR of 8.8% during the forecast period

SUIC Worldwide Holdings (OTC: SUIC) and Boom Fintech Inc., a fully-owned subsidiary of Beneway Holdings Group, Ltd USA, recently announced a financing planning with BD Bankers to access credit of up to $100 million in Intellectual Property ("IP") and equipment lending financing intended for the integration of advance systems and fintech patents held by Boom Fintech Inc. The new development brings substantial support for the company's global partner merchants and franchisees, bolstering supply chain integrations for suppliers and accelerating plans for an initial public offering of Beneway USA (

SUIC Worldwide Holdings Ltd. (OTC: SUIC) provides research and development, venture financing and investment for private and public companies that develop products and services in the areas of Internet of Things, cloud computing, mobile payments, Big Data, blockchain, artificial intelligence and global franchising. The company seeks to enhance and streamline existing processes and establish new and exciting business models that will create revolutionary products and services.

SUIC is the largest shareholder and major operating partner of Beneway Holdings Group. The I.Hart Group, a subsidiary of Beneway, currently operates 150 global chain and franchised locations under a variety of brands. It is working on integrating more successful chains to enter the U.S. chain and franchise market in all 50 states. It is replicating its successful multi-branding business model and teaming up with top U.S. real estate firms, shopping malls and associated groups to expand and achieve its target of 750 chain and franchise locations in the near future.

The company is headquartered in Flushing, New York, with offices in San Francisco, Taiwan and Malaysia.


SUIC works with Beneway in several business ventures, with focus on the following:

  • Fintech – Through Boom Fintech, the major subsidiary of Beneway USA, the company holds nine revolutionary fintech patents. Boom Fintech integrates payment systems, electronic invoice devices, mobile cash registers, POS system devices and ERP, as well Big Data + AI and other services, to ALL-IN-ONE products that provide standardized intellectual property that’s modular to all industries, from chain department stores to night market vendors. Beneway Holdings Group connects borrowers and lenders, building strategic partnerships by bridging the various stakeholders to provide a holistic financial delivery ecosystem and to integrate advanced systems and finance its global merchants and franchisees.
  • Food Industry Supply Chain Integration – SUIC and Beneway will partner with international trade financiers to support the huge demand for raw material import/export between the U.S. and Asia. SUIC and Beneway are looking to raise funds from an IPO and the capital markets to support mergers and acquisitions of U.S. mid- and upper-stream food industry suppliers.
  • Global Chain and Franchise Expansion – Through I.Hart catering group, SUIC and Beneway are working to bring reputable and distinguished overseas food product brands to the U.S. and around the world. It is working on integrating more successful chains to enter the U.S. chain and franchise market in all 50 states. It is replicating its successful multi-branding business model and teaming up with top U.S. real estate firms, shopping malls and associated groups for faster expansion.
  • Other Supply Chain Integration – Beneway has identified several additional industries for future expansion, including medical and health care, high-tech digital AI systems, environmental protection and energy-related production.

Market Opportunity

An analysis by Growth Market Reports, a full-service market research and business consulting organization, estimated that the value of the global Asian food market was $437.15 billion in 2022. The market value is projected to reach approximately $805.08 billion by 2031, expanding at a CAGR of 7.1% during the forecast period.

Asian cuisine is well known for its diversity, with a wide range of flavors, ingredients and cooking techniques influenced by various factors such as climate, geography, history and cultural practices. The report states that Asian food outlets are expanding at a tremendous rate in the U.S. and Europe due to rising consumer demand. Demand is driven by various factors, including the growing interest in global authentic flavors and the nutritional benefits that Asian food offers. Consumers have become increasingly exploratory with their food choices, according to the report.

McKinsey Consultants estimate that, by 2025, the global supply chain financial market will reach $20 trillion. At present, 60% of the global participants are small and medium-sized retail companies, representing the target customers of SUIC and its subsidiary. Recent Juniper Research shows that global digital commerce transaction value will also pass $20 trillion by 2027.

Management Team

Hank Wang is CEO of SUIC. Since 2018, he has served as CEO of the I.Hart Group. Prior to joining I.Hart, he was Secretary General of Taiwan Quantitative Hedging Development Association. He graduated from Tamkang University in Taiwan with a Bachelor of Finance degree.

Elena Lin is associate CFO of SUIC. She previously served as CEO of Monga Chicken. In 2015, she was recognized as one of Taiwan’s Top 100 Managers of the Year. She holds a master’s degree from the Kaohsiung University of Hospitality and Tourism’s Institute of Food Culture and Catering Innovation in Taiwan.

Elton Han is associate CTO of SUIC. He is also currently Director of Food and Beverage Development for the I.Hart Group. He also holds a position with the Taiwan International Young Chefs Association. He previously served as Executive Chef of Hanbilou, Huashan Guanzhi, Daye Group.

SUIC Worldwide Holdings Ltd. (OTC: SUIC), closed Friday's trading session at $1.37, off by 12.2919%, on 400 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.95/$3.00.

Recent News

Freight Technologies Inc. (NASDAQ: FRGT)

The QualityStocks Daily Newsletter would like to spotlight Freight Technologies Inc. (NASDAQ: FRGT).

Temporary railroad shutdowns in December 2023 stranded nearly 10,000 rail cars on both sides of the U.S. and Mexico border with embargoed goods on over 60 trains

With disruptions to cross-border trade on the rise, companies are seeking more reliable ways to organize, facilitate, and monitor their cross-border shipments

Fr8Tech, a tech company on a mission to revolutionize cross-border shipping, has positioned itself as the go-to brand for such services through its Fr8App system

Fr8App seamlessly connects shippers with carriers and drivers, and offers comprehensive real-time tracking, fleet management, live pricing, and transportation management

The ongoing migrant crisis has exposed the downsides of reliance on America's railroad network ( Two international railway crossing bridges in Texas were temporarily shut down in December 2023 following a reported surge in smuggling of migrants through Mexico by train.  The shutdown stranded nearly 10,000 rail cars on both sides of the border, with goods embargoed on over 60 trains every day of the closure ( Situations like these have highlighted the value of a reliable and dependable way to organize, facilitate, and monitor cross-border shipments, especially within the USMCA (United States-Mexico-Canada Agreement) region. Freight Technologies (NASDAQ: FRGT) ("Fr8Tech"), a tech company that is transforming cross-border shipping by offering carriers and shippers unmatched flexibility, visibility, and simplicity, has been at the forefront of pushing for such services, mainly through its Fr8App system that has proven its reliability and versatility over time.

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

  • Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
  • Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
  • Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
  • Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
  • Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
  • Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Commitment to the Environment

Through its core focus on technology, Fr8Tech seeks to reduce the carbon footprint of the logistics industry. Its solutions aim to minimize empty miles for transportation firms and reduce overall paper consumption.


Fr8University is an educational program offering classroom and on-the-job training for Fr8Tech team members. Through the program, employees learn in-depth business fundamentals and applications along the truckload freight industry value chain.

Led by corporate educator Mario Mena, Fr8University is designed as an investment in the company’s human capital, providing an opportunity to communicate Fr8Tech’s corporate culture while accelerating operational growth.

Market Outlook

Fr8Tech’s established foothold in Mexico is key to its current efforts to promote sustainable growth in the cross-border shipping industry. Ongoing disruption in U.S.-Chinese trade relations have strengthened Mexico’s status as the largest trading partner of the U.S., with cross-border annual freight spending estimated at $385 billion according to data from the U.S. Department of Transportation. Annual domestic shipping in Mexico is estimated at $34 billion, while annual domestic shipping in the U.S. is estimated to total $732 billion.

Despite the size of this industry, fragmentation and inefficiencies prevail in the space. Thousands of legacy brokers, tens of thousands of shippers and hundreds of thousands of carriers still rely on outdated systems to arrange transport, spending hours on the phone negotiating pricing, waiting days to find trucks and drivers, preparing and printing forms, and operating without tracking or visibility. Add in cross-border complexity relating to customs and additional paperwork, and you have an industry ripe for technological disruption.

Fr8Tech’s recent revenue growth trends have highlighted the company’s efforts to capitalize on this opportunity. In 2021, Fr8Tech achieved revenues of $21.5 million, marking a year-over-year increase of 134%. The company issued revenue guidance for fiscal 2022 of $40 million in a February 9, 2022, press release, which would account for a further 86% year-over-year increase.

Management Team

Javier Selgas is CEO and a Director of Freight Technologies Inc. and Freight App Inc. He brings to the company over 15 years of experience developing technology and digital marketing strategies, including serving as Country Manager for Osigu, Spain, and as head of AJEgroup’s IT division for the Asia-Pacific region. Prior to joining Fr8Tech, Mr. Selgas founded digital marketing agency Lanzadera Online. He has also served as an IT consultant to major corporations, including Endesa and Ibermatica.

Mike Flinker is President of Fr8Tech. He has over four decades of experience in the transportation industry, with 30+ years focused on cross-border logistics. Prior to joining Fr8Tech, Mr. Flinker founded FLS Transportation, the largest cross-border logistics company in Canada. He also previously held positions with Clarke Transport Inc., Canadian Pacific and Reimer Express Inc. (a division of Roadway Express).

Paul Freudenthaler is the company’s CFO and Secretary to the company Board. He has over 30 years of financial expertise, having previously served as CFO for several leading companies across multiple countries, including Macquarie in Mexico, Old Mutual in Latin America and Ascentium Capital in the U.S. Mr. Freudenthaler’s experience include leadership roles from which he guided IPOs and M&A transactions.

Luisa Lopez is COO of Fr8Tech. She brings to the company 25+ years of management experience in logistics, supply chain, operations and customer service. Ms. Lopez previously served as a Director of Landstar, where she was responsible for commercial and client development strategies in the Mexican market. Additionally, she managed more than 2,000 transport units specialized in staff and school mobility while with Traxion in Mexico.

Freight Technologies Inc. (NASDAQ: FRGT), closed Friday's trading session at $0.9465, off by 2.2211%, on 138,105 volume. The average volume for the last 3 months is 537,076 and the stock's 52-week low/high is $0.90/$34.10.

Recent News

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF)

The QualityStocks Daily Newsletter would like to spotlight First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) .

The race to cut greenhouse-gas emissions and achieve carbon neutrality by mid-century has left businesses in energy-intensive industries scrambling to cut their energy use. With most of the developed world's electricity coming from fossil-fuel-fired power plants, sectors such as data storage, which require a lot of power to run, contribute to a significant portion of global emissions. Efficient software use could be the key to helping data centers cut down on energy use and limit their impact on the environment. Data centers are facilities that store and power servers that house the cloud, or online storage facilities that allow people to store and retrieve their data without having to invest in physical storage media such as hard drives. Other efforts, such as the activities of mining companies such as First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF), are focusing on stepping up the availability of the critical metals that will play a pivotal role in the green-energy transition. All these efforts will eventually converge and result in the accelerated uptake of green energy in all industries and sectors.

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

The company is headquartered in Vancouver, British Columbia.

Tellurium and the Green Energy Revolution

Tellurium has a key role to play in the ongoing green energy revolution. It is widely used in the manufacturing of photovoltaic cells for solar panels.

Despite this utility, ongoing trade tensions between China and the U.S. create implications for both tellurium and the production of cadmium-tellurium solar cells. Earlier this year, China announced plans to restrict exports of critical metals gallium and germanium, both essential for the production of semiconductors. For reference, China produces around 80% of the world’s gallium and approximately 60% of the world’s germanium.

China’s recent trade restrictions amplify the fragility of the North American tellurium supply, as the Asian nation currently produces about 60% of the world’s tellurium. This sustained supply vulnerability is why First Solar, the United States’ largest solar panel producer, set up a worldwide search for tellurium deposits in the mid-2000s.

“In North America alone, our understanding is that First Solar looked at over a hundred tellurium properties,” First Tellurium CEO Tyrone Docherty stated in a news release. “Their number one property by far, which they acquired, was the Colorado Klondike which we now control.”

The U.S. is now looking to secure safe, domestic sources of tellurium and many other critical metals to pre-empt potential shortages. The Biden administration has instituted a stream of policies, particularly the U.S. Inflation Reduction Act, to source solar components from North America and other “friendly” jurisdictions.

As the only junior mining company in the world focused on tellurium exploration, First Tellurium is ahead of the curve in capitalizing on these initiatives to establish strategic, domestic supplies of key resources for solar panel manufacturers.

First Tellurium’s ESG Initiatives

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.



Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has begun permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (IP) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (CGS), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (IEA) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc., taking over when it had a market cap of $4 million. With limited resources in a difficult market environment, he raised more than $30 million and advanced Quinto’s Quebec iron ore property to a viable project. Quinto later sold for $175 million, with Quinto management taking shares of the purchaser, Consolidated Thompson Iron Mines, amounting to approximately 20-21% of that company. Consolidated Thompson Iron Mines sold two years later for $4.9 billion, giving the former Quinto team an enterprise value of approximately $1 billion. From 2012 to 2018, Mr. Docherty was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

First Tellurium Corp. (OTCQB: FSTTF), closed Friday's trading session at $0.06395, off by 0.389408%, on 3,000 volume. The average volume for the last 3 months is 40,824 and the stock's 52-week low/high is $0.047785/$0.1408.

Recent News

Golden Triangle Ventures Inc. (OTC: GTVH)

The QualityStocks Daily Newsletter would like to spotlight Golden Triangle Ventures Inc. (GTVH).

CEO interview series provides Golden Triangle with a platform to share its story with an expanded audience

Collaboration with Cayenne Consulting will provide key strategic planning and expertise in development of Destino Ranch

Destino Ranch aims to redefine luxury entertainment and hospitality experiences

As Golden Triangle Ventures (OTC: GTVH) and its entertainment division, Lavish Entertainment, focus on the development of Destino Ranch, a one-of-a-kind immersive entertainment venue, the company is working to increase awareness of the project. As part of these efforts, Golden Triangle is partnering with NowMedia Networks to broadcast 12 weekly interviews with GTVH CEO and president Steffan Dalsgaard (

Golden Triangle Ventures Inc. (OTC: GTVH) is a multifaceted consulting company pursuing ventures in the health, entertainment and technology industries, with many additional projects being developed that provide synergistic values to these divisions. The company aims to purchase, acquire and/or joint venture with established entities that management can help assist and develop into unique opportunities.

Additionally, GTVH provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business development objectives. The goods and services represented are driven by innovators who have passion and commitment to these marketplaces.

The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent these three sectors in which the company aims to do business.

Health Division – Global Health Services

Global Health Services is a wholly owned subsidiary of Golden Triangle Ventures (operating under its Health Division). Dedicated to the promotion of well-being and natural wellness, the company currently does business in the industrial hemp/CBD industry. Additionally, the company has a vision to promote, market and generate sales for a myriad of products and services which include a full retail line of high-end, all-natural health, wellness and beauty products.

To help achieve this vision, Global Health Services is in the process of further developing an extensive online portal that will support the multiple verticals under the company and provide a one-stop-shop for all of the company’s products and services. Moreover, to support overarching business goals, senior management tirelessly works on acquiring and building an array of profitable assets and projects.

Entertainment Division – Lavish Entertainment

Lavish Entertainment (EpicRaves) is a wholly owned subsidiary of Golden Triangle Ventures under its Entertainment Division. Operating out of Las Vegas, Nevada, the company started doing business in 2017 and was established with a vision of becoming a nationally recognized concert production company. The company currently has more than 30,000 national followers and nearly 100 team members who have helped the company successfully organize some of the most exciting Electronic Dance Music concerts in Las Vegas.

Lavish Entertainment is currently doing business as EpicRaves, which will eventually become a wholly owned subsidiary of Lavish Entertainment as the company expands its business into a variety of other forms of entertainment. The company is currently building a unique virtual reality platform to help expand on its live events, and it is working to acquire a 68,000 sq. ft. event center with a vision to develop one of the most advanced event centers in the world.

Technology Division – HyFrontier Technology

HyFrontier Technologies is a wholly owned subsidiary of Golden Triangle Ventures under its Technology Division. The company owns a patent-pending process and device technology called HyGrO, which is a molecular hydrogen and oxygen delivery system for agriculture. Golden Triangle Ventures is assisting the company in commercializing the HyGrO unit for farm and home use in markets across the globe. HyFrontier Technologies has a mission to improve global crop production efficiency by producing hydrogen and oxygen directly in the water stream.

This technology can be used on any species of plant life in nearly any grow medium. Additionally, the system can be retrofitted to wellheads for large-scale agricultural projects, indoor grow operations and small farms or utilized for a multitude of residential home and garden applications. In-house testing has shown evidence that hydrogen is capable of increasing crop yields by up to 25% and, in many circumstances, a much higher amount. Larger root systems and better overall plant health were also observed by watering plants with the HyGrO unit. Universities and multiple third-party testing facilities are currently working to validate the HyGrO technology, and all preliminary results are extremely positive.

To push the development and commercialization of the technology, management is now in the process of moving the company headquarters from Colorado to Florida, which will transition its operations into a 7,800 sq. ft. state-of-the-art manufacturing facility. The company recently executed a three-year lease with an option to purchase the entire 24,000 sq. ft. building, which will help the business in achieving its ultimate goal of commercializing this technology to the world.

Food & Wine Division – Napa Wine Brands

Napa Wine Brands is a wholly owned subsidiary of Golden Triangle Ventures which is a synergistic business with a mission of providing a world-class portfolio of unique brands birthed from Napa Valley and Sonoma Valley in the heart of California’s Wine Country.

The company has a commitment to manufacture and distribute specialty wines, foods and unique items while tapping into an array of hidden markets in the food and beverage industry. With extensive resources and award-winning products, Napa Wine Brands aims to develop some of the most desirable products in today’s market. Originated by some of the most profound experts in Napa Valley, the company’s vision is to broaden the horizon of a traditional food and wine company by creating a platform different than anything seen in the Northern Hemisphere.

Napa Wine Brands has an array of fully developed products and services that provide value to the other divisions under Golden Triangle Ventures. The company is now preparing the launch of several brands, products and services that are market-ready and will immediately turn into cash-positive businesses. Golden Triangle Ventures will provide a full support system and assist management of Napa Wine Brands in growing this company into another fun, exciting and profitable division of Golden Triangle Ventures.

Recent Updates

  • On May 26, 2021, Golden Triangle announced its acquisition of The Lodge Winery & Olive Oil Co. under the company’s Napa Wine Brands subsidiary. The Lodge Winery & Olive Oil Co. is an established wine brand that produces award-winning wines, olive oils and wine vinegars. “Our marketing team is now ready to launch an in-depth program focused on driving our products into big box stores, smaller retail outlets, online platforms and many other avenues,” Steffan Dalsgaard, CEO of Golden Triangle, stated in a news release announcing the acquisition. “We are working directly with [Napa Wine Brands CEO] Arron [Johnson] and his team to grow their bulk inventory and launch all of these products for the world to enjoy.”
  • On May 20, 2021, Golden Triangle announced its entry into a letter of intent to acquire Sonder Fulfillment LLC, a leader in the industrial hemp and CBD space that is dedicated to driving forward the most powerful and efficacious cannabinoid products in the world. “Over the past two years, our operating partners have compiled a team of the best minds in the industrial hemp industry to create a totally vertical operation from seed to shelf,” Joshua Weaver, CEO of Sonder Fulfillment, stated in a news release announcing the LOI. “This acquisition by Golden Triangle Ventures will fully capitalize our operations and allow us to further expand our product lines and enter into new markets across the globe.”
  • On May 19, 2021, Golden Triangle announced the execution of a formal agreement with Robert “Bo” DuBose to purchase the remaining 49% of HyFrontier Technologies Inc., giving Golden Triangle 100% ownership of the technology company. “This acquisition has been something that Bo and I have been working towards for quite some time and we are both incredibly happy to have this executed,” Dalsgaard stated in a news release announcing the acquisition. “We knew that completing this agreement would show the world that we are both fully committed to our shareholders and the brilliant future of this revolutionary company.”
  • On May 12, 2021, Golden Triangle announced its acquisition of a top tier, professional sound system and formed a partnership with SuperKollider Sound LLC to provide a strategic benefit to the company’s entertainment division under Lavish Entertainment Inc. “We are very excited to acquire this unbelievable sound system,” Dalsgaard stated in a news release announcing the acquisition. “Hennessey Sound Design has always been one of my favorite systems on the market, and the team at SuperKollider Sound are true professionals in this space.”

Management Team

Steffan Dalsgaard is the Founder & Executive Chairman of Golden Triangle. He has a background in business development, with over a decade of experience representing and consulting with dozens of private and public companies. Mr. Dalsgaard consults with companies on all of their corporate objectives while providing a professional and corporate face to their organizations. He has built a strong reputation in the public relations industry and has a mission to work with emerging growth companies that are positioned to become significant businesses in their respective fields.

Robert DuBose is the company’s Chief Innovations Officer & Director and the CEO of HyFrontier Technologies Inc. Mr. DuBose is responsible for the success of the HyGrO product in the agricultural market. His experience in the design and production of hydrogen equipment goes back more than a decade, including PEMFC technologies since 2009 with his company, Aquafuel Inc. Mr. DuBose was raised in the farming and machine shop business, where he learned firsthand how much work and love goes into a successful crop, as well as how elements, which are out of the farmers control, can have adverse effects on finances. His belief that being able to deliver a solution to increase growth, yield, health, stamina of crops and profitability for farmers would be a win-win for all led him to create the HyGrO product.

Stuart Seim is the Chief Development Officer & Director of Golden Triangle. He began his career as an associate professor at the University of Manitoba in the field of outdoor and environmental education after receiving his master’s degree and completing advanced educational studies. Coming from a family with an extensive financial background, Mr. Seim became a stockbroker for major regional financial firm Robert W. Baird. In a short time, he became the Branch Manager for Baird in Minneapolis, Minnesota, while also serving as a Managing Director for Baird. During this time, Mr. Seim also served on the board of an industrial hearing company, which he helped to launch as a new company (The TK Group). Mr. Seim currently resides in Colorado, where he is an advisor to several organizations.

Golden Triangle Ventures Inc. (GTVH), closed Friday's trading session at $10.83, up 4.4359%, on 81,689 volume with 697 trades. The average volume for the last 3 months is 269,609 and the stock's 52-week low/high is $2.33999991/$20.0783996.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.